Market Overview:
The global erectile dysfunction treatment drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of erectile dysfunction, rising awareness about available treatments, and growing demand for novel therapies. The phosphodiesterase type 5 inhibitors segment is expected to account for the largest share of the global erectile dysfunction treatment drugs market in 2018. This segment is anticipated to grow at a CAGR of 5.7% during the forecast period from 2018 to 2030 due to its high efficacy and safety profile.
Product Definition:
Erectile dysfunction drugs, also called phosphodiesterase type 5 inhibitors, are used to treat erectile dysfunction (ED), a condition in which a man cannot get or keep an erection. The most common drug in this class is sildenafil (Viagra). These drugs work by increasing blood flow to the penis.
Phosphodiesterase Type 5 Inhibitors:
Phosphodiesterase type 5 inhibitors, it's usage and growth factor in erectile dysfunction treatment drugs market: The global phosphodiesterase type 5 inhibitors, it's usage and growth factor in erectile dysfunction treatment drugs market size was valued at USD 2.8 billion in 2015. It is expected to witness a CAGR of XX% during the forecast period.
Prostaglandin E1:
Prostaglandin E1 is a prostacyclin and it's analog. It has been observed to be effective in the treatment of erectile dysfunction by enhancing penile blood flow. By inhibiting platelet aggregation, it helps in increasing the inflow of blood into the penis for sexual stimulation.
prostaglandins (PGs) are natural substances produced by certain body parts such as prostate gland, thymus,.
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and other medical facilities. Hospitals were the largest revenue-generating centers due to factors such as a large patient base and prevalence of chronic diseases that require long term treatment. This factor has led to an increase in demand for erection drugs in this region.
The others segment includes companies offering online services as well as those operating outside of the healthcare sector (for instance, via direct sales). These companies are involved in various activities such as manufacturing/importation/exportation of erection drugs with niche applications or usage patterns. The growth rate of this segment can be attributed to increasing demand from non-healthcare professionals for effective treatment options without traveling frequently or staying overnight at a hospital bedside.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in the prevalence of erectile dysfunction among all age groups. Moreover, high demand for PDE5 inhibitors due to their efficiency and low cost is driving this regional market. The region is expected to maintain its dominance throughout the forecast period on account of increasing R&D investments by major companies and rising healthcare expenditure by governments.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure, growing patient awareness levels about available treatment options & availability of effective therapies for ED and other sexual disorders coupled with promotional activities by various organizations such as WHO & APICER that provide free samples & information regarding these drugs leading to an increase in prescriptions and consequently sales of PDE5 inhibitors especially Viagra (sildenafil citrate) which accounted for more than 80% share of this segment globally.
Growth Factors:
- Increasing prevalence of erectile dysfunction
- Growing awareness about available treatments for erectile dysfunction
- Rising demand for effective and safe treatments for erectile dysfunction
- Availability of generic versions of branded drugs
- Growing investment in research and development
Scope Of The Report
Report Attributes
Report Details
Report Title
Erectile Dysfunction Treatment Drugs Market Research Report
By Type
Phosphodiesterase Type 5 Inhibitors, Prostaglandin E1
By Application
Hospitals, Clinic, Others
By Companies
Pfizer Inc., Dong-A Pharmaceutical Co. Ltd, Vivus, Inc., Meda Pharmaceuticals, Bayer AG, Johnson & Johnson Services, Apricus Biosciences, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
154
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Erectile Dysfunction Treatment Drugs Market Report Segments:
The global Erectile Dysfunction Treatment Drugs market is segmented on the basis of:
Types
Phosphodiesterase Type 5 Inhibitors, Prostaglandin E1
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer Inc.
- Dong-A Pharmaceutical Co. Ltd
- Vivus, Inc.
- Meda Pharmaceuticals
- Bayer AG
- Johnson & Johnson Services
- Apricus Biosciences
- Eli Lilly
Highlights of The Erectile Dysfunction Treatment Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Phosphodiesterase Type 5 Inhibitors
- Prostaglandin E1
- By Application:
- Hospitals
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Erectile Dysfunction Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There are many different types of drugs used to treat erectile dysfunction. Some of the most common treatments include phosphodiesterase type 5 inhibitors (such as sildenafil), penile injections (such as alprostadil), and vacuum devices.
Some of the key players operating in the erectile dysfunction treatment drugs market are Pfizer Inc., Dong-A Pharmaceutical Co. Ltd, Vivus, Inc., Meda Pharmaceuticals, Bayer AG, Johnson & Johnson Services, Apricus Biosciences, Eli Lilly.
The erectile dysfunction treatment drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Erectile Dysfunction Treatment Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Erectile Dysfunction Treatment Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Erectile Dysfunction Treatment Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Erectile Dysfunction Treatment Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Erectile Dysfunction Treatment Drugs Market Size & Forecast, 2018-2028 4.5.1 Erectile Dysfunction Treatment Drugs Market Size and Y-o-Y Growth 4.5.2 Erectile Dysfunction Treatment Drugs Market Absolute $ Opportunity
Chapter 5 Global Erectile Dysfunction Treatment Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
5.2.1 Phosphodiesterase Type 5 Inhibitors
5.2.2 Prostaglandin E1
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Erectile Dysfunction Treatment Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Erectile Dysfunction Treatment Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Erectile Dysfunction Treatment Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Erectile Dysfunction Treatment Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
9.6.1 Phosphodiesterase Type 5 Inhibitors
9.6.2 Prostaglandin E1
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Erectile Dysfunction Treatment Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
10.6.1 Phosphodiesterase Type 5 Inhibitors
10.6.2 Prostaglandin E1
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Erectile Dysfunction Treatment Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
11.6.1 Phosphodiesterase Type 5 Inhibitors
11.6.2 Prostaglandin E1
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Erectile Dysfunction Treatment Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
12.6.1 Phosphodiesterase Type 5 Inhibitors
12.6.2 Prostaglandin E1
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Erectile Dysfunction Treatment Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Erectile Dysfunction Treatment Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Erectile Dysfunction Treatment Drugs Market Size Forecast by Type
13.6.1 Phosphodiesterase Type 5 Inhibitors
13.6.2 Prostaglandin E1
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Erectile Dysfunction Treatment Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Erectile Dysfunction Treatment Drugs Market: Competitive Dashboard
14.2 Global Erectile Dysfunction Treatment Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer Inc.
14.3.2 Dong-A Pharmaceutical Co. Ltd
14.3.3 Vivus, Inc.
14.3.4 Meda Pharmaceuticals
14.3.5 Bayer AG
14.3.6 Johnson & Johnson Services
14.3.7 Apricus Biosciences
14.3.8 Eli Lilly